Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.60 |
| ▸ | MAPT | P10636 | 8/20 | 0.60 |
| ▸ | MEN1 | O00255 | 7/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 7/20 | 0.53 |
| ▸ | NPC1 | O15118 | 6/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21729933 | 0.80 | TDP1 (0.79) | TDP1KMT2AMAPTMEN1LMNA | |
| SCHEMBL483903 | 0.71 | ALDH1A1 (0.71) | TDP1KMT2AMAPTMEN1LMNA | |
| SCHEMBL2020949 | 0.70 | RAB9A (0.71) | TDP1KMT2AMAPTMEN1LMNA | |
| SCHEMBL2020946 | 0.70 | RAB9A (0.71) | TDP1KMT2AMAPTMEN1LMNA | |
| SCHEMBL4199839 | 0.70 | ALDH1A1 (0.69) | TDP1KMT2AMAPTMEN1LMNA | |
| SCHEMBL21729898 | 0.68 | KMT2A (0.78) | TDP1KMT2AMAPTMEN1LMNA | |
| SCHEMBL21626747 | 0.68 | NPC1 (0.83) | TDP1KMT2AMAPTMEN1LMNA | |
| SCHEMBL12218394 | 0.68 | KMT2A (0.73) | TDP1KMT2AMAPTMEN1LMNA | |
| SCHEMBL21729902 | 0.67 | KMT2A (0.68) | TDP1KMT2AMAPTMEN1LMNA | |
| SCHEMBL5647994 | 0.67 | ALDH1A1 (0.59) | TDP1KMT2AMAPTMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220062281-A1 | INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION | NAT CENTRE FOR BIOLOGICAL SCIENCES TIFR (IN) | 2022-03-03 | — | — | US | disclosed |
| WO-2020035880-A1 | INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION | NATIONAL CENTRE FOR BIOLOGICAL SCIENCES-TIFR (IN) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062281-A1 | INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION | CD4, CD14, CD69 | TDP1 3710/4885KMT2A 2540/4885MAPT 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.